Human papilloma virus immunization in adolescent and young adults: A cohort study to illustrate what events might be mistaken for adverse reactions

Pediatric Infectious Disease Journal

Volumn 26, Issue 11, 2007, Pages 979-984

  Siegrist, Claire Anne ^a   Lewis, Edwin M ^b   Eskola, Juhani ^c   Evans, Stephen J W ^d   Black, Steven B ^e  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b DIVISION OF RESEARCH   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e STANFORD UNIVERSITY   (United States)

Author keywords

Adolescent immunization; Autoimmunity; Public health; Temporal associations; Vaccine safety

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANAPHYLACTIC SHOCK; ARTICLE; ASTHMATIC STATE; ATOPIC DERMATITIS; ATOPY; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; BELL PALSY; CONSULTATION; CROHN DISEASE; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG HYPERSENSITIVITY; DRUG SAFETY; EMERGENCY CARE; FEMALE; HOSPITALIZATION; HUMAN; IMMUNIZATION; IRIDOCYCLITIS; JUVENILE DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; KERATITIS; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; MYALGIA; MYOSITIS; OPTIC NEURITIS; OUTPATIENT CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID DISEASE; THYROTOXICOSIS; TREATMENT OUTCOME; ULCERATIVE COLITIS; URTICARIA; VACCINATION REACTION; VIRUS INFECTION; WART VIRUS;

EID: 36749010976     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e318149dfea     Document Type: Article

References (26)

1. Kuehn BM. CDC panel backs routine HPV vaccination. JAMA. 2006;296:640-641.
2. Zimet GD. Improving adolescent health: focus on HPV vaccine acceptance. J Adolesc Health. 2005;37(6 suppl):S17-S23.
3. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006;117:1486-1493.
4. Waller J, Marlow LA, Wardle J. Mothers' attitudes towards preventing cervical cancer through human papillomavirus vaccination: a qualitative study. Cancer Epidemiol Biomarkers Prev. 2006;15:1257-1261.
5. Slomovitz BM, Sun CC, Frumovitz M, et al. Are women ready for the HPV vaccine? Gynecol Oncol. 2006;103:151-154.
6. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927.
7. Denis F, Goudeau A, Aufrere A. Vaccination against hepatitis B in France in 1996. Bull Soc Pathol Exot. 1998;91:37-40.
8. Herroelen L, de Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet. 1991;338:1174-1175.
9. Marshall E. A shadow falls on hepatitis B vaccination effort. Science. 1998;281:630-631.
10. DeStefano F, Weintraub ES, Chen RT. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology. 2005;64:1317.
11. Comenge Y, Girard M. Multiple sclerosis and hepatitis B vaccination: adding the credibility of molecular biology to an unusual level of clinical and epidemiological evidence. Med Hypotheses. 2006;66:84-86.
12. Denis F, Abitbol V, Aufrere A. Evolution of strategy and coverage rates for hepatitis B vaccination in France, a country with low endemicity. Med Mal Infect. 2004;34:149-158.
13. Duclos P. Safety of immunization and adverse events following vaccination against hepatitis B. J Hepatol. 2003;39(suppl 1):S83-S88.
14. Guillain-Barré Syndrome Among Recipients of Menactra® Meningococcal Conjugate Vaccine - United States, June-July 2005, MMWR Morb Mortal Wkly Rep. 2005;54:1023-1025.
15. Update: Guillain-Barré Syndrome Among Recipients of Menactra® Meningococcal Conjugate Vaccine - United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep. 2006;55:1120-1124.
16. Schmiedeskamp MR, Kockler DR. Human papillomavirus vaccines. Ann Pharmacother. 2006;40:1344-1352.
17. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116:1167-1173.
18. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366:991-998.
19. Halsey NA. The science of evaluation of adverse events associated with vaccination. Semin Pediatr Infect Dis. 2002;13:205-214.
20. Ellenberg SS, Braun MM. Monitoring the safety of vaccines: assessing the risks. Drug Saf. 2002;25:145-152.
21. Nigrovic LE, Thompson KM. The Lyme vaccine: a cautionary tale. Epidemiol Infect. 2007;135:1-8.
22. Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity- "vaccinosis": a dangerous liaison? J Autoimmun. 2000;14:1-10.
23. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet. 2003;362:1659-1666.
24. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13:700-722.
25. Demicheli V, Rivetti A, Di Pietrantonj C, Clements CJ, Jefferson T. Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review. J Viral Hepat. 2003;10:343-344.
26. DeStefano F, Verstraeten T, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis. Expert Rev Vaccines. 2002;1:461-466.